Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on May 27, 2025
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Completion of Enrollment of the Global Phase 2b Study Evaluating Naronapride in Gastroparesis (MOVE-IT)
GlobeNewswire
·
May 27, 2025
ROSCREA, Ireland and FREIBURG, Germany, May 27, 2025 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) …
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced an upcoming presentation at the …
MIMEDX to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual …
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
GlobeNewswire
·
May 27, 2025
LONDON, May 27, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced the publication of preclinical proof-of-concept data for FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease in Molecular Therapy, the flagship …
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the …
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire
·
May 27, 2025
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Merus to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewswire
·
May 27, 2025
NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
Emory Healthcare Researchers Use Dynamic Digital Radiography to Compare Shoulder Improvement of Two Surgical Interventions for Massive Irreparable Rotator Cuff Tears
GlobeNewswire
·
May 27, 2025
WAYNE, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., congratulates Emory Healthcare researchers on the publication of a new study using Dynamic Digital Radiography (DDR) to compare shoulder biomechanics in patients after …
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 27, 2025
- Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) …
Merus hält Vorträge auf bevorstehenden Investorenkonferenzen
GlobeNewswire
·
May 27, 2025
UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge sowie Antikörper-Wirkstoff-Konjugate ( …
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
GlobeNewswire
·
May 27, 2025
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May …
DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal
GlobeNewswire
·
May 27, 2025
DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today …
Merus annonce sa participation aux prochaines journées Investisseurs
GlobeNewswire
·
May 27, 2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 27 mai 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société d’oncologie développant des anticorps multispécifiques de pleine longueur novateurs et des conjugués anticorps-médicaments ( …
Theriva™ Biologics anuncia la presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en ASCO 2025 y la reunión de investigadores para revisar los datos preliminares del ensayo VIRAGE de Fase 2b del VCN-01 para el…
GlobeNewswire
·
May 27, 2025
- Los resultados clínicos y de seguridad del estudio de Fase 1 del VCN-01 (zabilugene almadenorepvec) en pacientes con retinoblastoma refractario se presentarán en una sesión de pósteres en la reunión anual de la Sociedad Americana de Oncología Clínica ( …
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
GlobeNewswire
·
May 27, 2025
Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation at a future medical meeting SYDNEY, …
Reflect Scientific, Inc. Announces Strategic Cost-Cutting Initiative to Reduce SG&A Expenses by Up to 35% in 2025
GlobeNewswire
·
May 27, 2025
OREM, Utah, May 27, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leading innovator in cryogenic cooling technologies, today announced a comprehensive initiative to reduce Selling, General …
Hydreight Launches Personalized Genetic Testing and Wellness Solution on VSDHOne Platform
GlobeNewswire
·
May 27, 2025
VANCOUVER, British Columbia and LAS VEGAS, May 27, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform delivering compliant mobile and telehealth …
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
GlobeNewswire
·
May 27, 2025
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, …
ORYZON to Provide Corporate Progress Updates at Several Events in May-June
GlobeNewswire
·
May 27, 2025
Foro MedCap 2025 BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a …